The Syk inhibitory properties of the Nilvadipine have been previously demonstrated in mouse models of AD and tauopathies (Paris et al., 2014), but more work is required to confirm that this is the mechanism through which it elicits the favorable responses described in this study. Here, SYK is linked to tauopathy.